Medical Report Review — Cost, Top Hospitals & Success Rates | MyMedicPlus

A medical report review — commonly called a second opinion — is the formal evaluation of a patient's existing medical records, laboratory results, imaging studies, and pathology by a specialist who was not involved in the initial diagnosis or treatment planning. It is distinct from a follow-up appointment with the same provider: the purpose is independent expert review that may confirm, refine, or substantially change the original conclusion.

In the modern era, second opinions are increasingly conducted remotely via telemedicine platforms, without the patient needing to travel to the reviewing institution. Digitised imaging (DICOM files), scanned pathology slides (whole-slide imaging — WSI), electronic health records (EHR), and secure file transfer have made high-quality asynchronous review by world-leading specialists accessible from any location.

A landmark study published in the Journal of Clinical Oncology (Payne et al., 2019) found that among 293 cancer patients who sought a second opinion at a major academic centre, 21% received a major change in diagnosis or treatment plan, and an additional 40% received minor modifications. For rare tumours and sarcomas, the major change rate exceeded 40%.

Medical report review is not a sign of distrust toward the treating physician — it is an internationally recognised best practice and is actively encouraged by organisations including the American Cancer Society, the National Cancer Institute, NICE (UK), and the European Society for Medical Oncology (ESMO).

A second opinion is most valuable — and sometimes critical — in the following situations:

1. New Cancer Diagnosis

Cancer diagnosis and staging determine treatment intensity, toxicity, and prognosis. Pathological misclassification occurs in an estimated 10–15% of solid tumour biopsies (American Journal of Clinical Pathology). Reclassification of breast cancer (e.g., HER2 status), lymphoma subtype, or sarcoma histotype can radically change management — from watchful waiting to aggressive chemotherapy, or vice versa. A second pathology review and tumour board evaluation at a specialist cancer centre is particularly important for rare tumours, soft tissue sarcomas, and borderline lesions.

2. Recommendation for Major Surgery

Any recommendation for high-risk, irreversible, or complex surgery — spinal fusion, cardiac bypass, total joint replacement, liver or pancreatic resection, total colectomy — warrants independent review. A second opinion can confirm that surgery is appropriate, identify that conservative management has not been adequately trialled, or reveal that a less invasive approach is available at a specialist centre.

3. Rare or Unusual Disease

Rare diseases (defined as affecting fewer than 1 in 2,000 in the EU) are frequently misdiagnosed — the average patient with a rare disease consults 7.3 physicians and waits 4.8 years before receiving a correct diagnosis (Orphanet data). Expert centres for rare diseases (European Reference Networks — ERNs; NIH Undiagnosed Diseases Programme) provide specialist review precisely because general hospital physicians may see fewer than one case per career.

4. Disputed, Inconsistent, or Uncertain Diagnosis

Where a diagnosis does not fully explain symptoms, where imaging and clinical findings are discordant, or where multiple physicians have offered different opinions, a structured second opinion review can synthesise the available evidence and provide clarity.

5. International Patients Planning Medical Travel

Before travelling abroad for treatment, it is essential that the proposed treatment plan is reviewed and confirmed by the destination specialist using the patient's actual records — not just a referral letter. This ensures the surgical team understands the full clinical picture and can plan appropriately.

6. Disagreement with a Proposed Treatment

Patients who feel uncertain, rushed, or unconvinced by a proposed treatment plan are entitled to independent review. Shared decision-making requires that patients are fully informed of alternatives — a second opinion can confirm or challenge the recommendation and ensure the patient's autonomy.

Any patient with an existing medical record, investigation result, or pathology report can request a second opinion. There are no clinical eligibility restrictions — it is a patient right, not a clinical intervention requiring specific criteria.

Your Legal Right to Medical Records

Access to medical records is a legal right in most countries:

• United States: Under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, patients have the right to access and obtain copies of their Protected Health Information (PHI) held by any covered entity (hospital, clinic, laboratory). Providers must respond within 30 days (extendable once to 60 days). Fees for copying must be reasonable.
• European Union and UK: Under the General Data Protection Regulation (GDPR) and UK GDPR, patients have a right of access (Subject Access Request — SAR) to their health data. Providers must respond within one calendar month at no charge for a first request.
• India: The Clinical Establishments Act and Digital Information Security in Healthcare Act (DISHA, draft 2018) provide patients with the right to access records; implementation varies by state and institution.
• International patients: Records from overseas institutions can legally be shared with reviewing physicians when authorised by the patient. A signed patient consent/release form is sufficient authorisation in most jurisdictions.

What Documents Are Needed?

A complete second opinion review requires: all imaging studies (CT, MRI, PET — preferably as DICOM files on CD/DVD or uploaded to a secure cloud link); pathology reports and, where available, digitised H&E glass slides or whole-slide images; laboratory results (blood counts, tumour markers, genetic/molecular testing); all prior clinic letters and operative notes; and a concise clinical summary from the patient or referring physician.

1. In-Person Expert Consultation at a Specialist Centre

The traditional model — the patient or their records are physically reviewed at an academic medical centre or specialist hospital. Allows direct examination by the reviewing physician and immediate face-to-face discussion. Best for complex cases where physical examination findings are critical (e.g., neurological examination, wound assessment). Examples: Mayo Clinic (Rochester, MN), Cleveland Clinic, Johns Hopkins, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Charité Berlin, Royal Marsden London.

2. Online / Asynchronous Second Opinion Service

Patients submit records electronically via a secure web portal; the reviewing specialist provides a written report within 3–10 business days. No travel required. Leading institutional online programmes:

• Mayo Clinic Online Second Opinion (MCOSO): Available for patients worldwide; oncology, cardiac, and neurological specialties are most commonly sought. Response in 8 business days (standard) or less than 48 hours (urgent). Fee-based; some insurance plans partially cover the cost.
• Cleveland Clinic MyConsult: Online second opinion platform covering 1,200+ specialists. Available globally. Turnaround 7–10 business days. Covers oncology, cardiology, neurology, and orthopaedics.
• MD Anderson Cancer Center Second Opinion: Oncology-specific; accepts international patients. Pathology and imaging review by subspecialty-trained oncologists and pathologists.
• Brigham and Women's Hospital Online Second Opinion: Multidisciplinary coverage; particularly strong for rare and complex diseases.
• Memorial Sloan Kettering Cancer Center Cancer Wise Second Opinion: Focuses on oncology and genomic profiling review.

3. Digital Pathology Second Opinion

Pathological diagnosis (tissue biopsy interpretation under the microscope) is the most critical element in cancer diagnosis. Digital pathology platforms allow glass slides to be scanned at high resolution (whole-slide imaging, WSI) and reviewed remotely by expert pathologists, eliminating the need to physically ship fragile glass slides. Platforms include PathAI, Proscia Concentriq, and institutional platforms at major cancer centres. Turn-around for digital pathology second opinion is typically 3–5 business days. For borderline or rare tumours, immunohistochemistry panels and molecular testing (FISH, PCR, next-generation sequencing) can be ordered remotely on archived paraffin blocks.

4. AI-Assisted Radiology Second Opinion

Artificial intelligence tools are increasingly used to assist radiologists in reviewing imaging. FDA-approved AI tools (e.g., Arterys for cardiac MRI, Viz.ai for stroke CT) flag potential findings for radiologist review. AI-assisted review does not replace subspecialty radiologist second opinion but can triage cases and reduce reading time. Teleradiology services (e.g., NightHawk Radiology, vRad) provide subspecialist radiological review of DICOM studies, particularly useful for international patients whose local radiologist may lack subspecialty expertise in rare tumour imaging.

5. Multidisciplinary Tumour Board Review

For cancer patients, presentation to a specialist institution's multidisciplinary team (MDT) or tumour board — which includes medical oncology, surgical oncology, radiation oncology, radiology, and pathology — provides a collective second opinion. International patients can have their cases presented at major centre tumour boards via video-link or secure file sharing. This is particularly valuable for cases where the optimal sequence of surgery, chemotherapy, and radiotherapy is uncertain.

The evidence for the value of second opinions in medicine is substantial:

• Diagnosis accuracy: A meta-analysis of studies on second opinions in oncology found that expert review changed diagnosis in 12–62% of cases, depending on tumour type and complexity (Nakhleh, Arch Pathol Lab Med, 2006). For soft tissue tumours and lymphomas, reclassification rates exceed 20%.
• Treatment modification: Among patients whose diagnosis was confirmed, a further 20–30% experienced modification of their treatment plan — adding or removing a modality, changing a drug, or altering sequencing. This may directly improve survival and quality of life.
• Patient empowerment and reassurance: Confirmation of an initial diagnosis by an independent expert significantly reduces patient anxiety and improves treatment adherence. Patients who have had a second opinion are more likely to proceed with recommended treatment with confidence.
• Avoiding unnecessary procedures: Second opinions sometimes reveal that a proposed surgery or treatment is not the current standard of care, or that equally effective and less invasive options exist — potentially sparing patients from unnecessary harm and cost.
• Access to clinical trials: Major academic centres reviewing a patient's case may identify eligibility for clinical trials not available at the original institution.
• Genomic and molecular testing: Specialist centres may recommend tumour molecular profiling (e.g., FoundationOne CDx, MSK-IMPACT) that was not ordered at the original centre, potentially identifying targetable mutations that open up precision therapy options.

Medical report review is generally without direct clinical risk (no procedure is performed), but practical limitations exist:

• Time delay: Seeking a second opinion takes time — typically 1–4 weeks from record request to reviewed report. For conditions where time to treatment is critical (acute leukaemia, sepsis, surgical emergency), delay must be carefully weighed. For most solid tumours and elective procedures, a 2–4 week delay for review does not adversely affect outcomes.
• Conflicting opinions: Receiving a second opinion that differs from the first does not automatically mean one is correct. A third opinion or tumour board review may be needed to resolve genuine diagnostic uncertainty.
• Incomplete records: If the reviewing institution does not receive all relevant records (original glass slides, full imaging series, operative reports), the review may be limited. The patient should ensure all records are transmitted before the review begins.
• Cost: Remote second opinion services at major US academic centres typically cost USD 500–2,500 per case (not always covered by insurance). International patients incur additional costs for record translation and courier/digital transfer.
• Psychological stress: Some patients find the process of seeking a second opinion emotionally difficult, particularly if the results confirm a serious diagnosis or if opinions conflict. Psychological support should be available during this process.
• Not a substitute for ongoing care: A second opinion report provides expert advice at a single point in time. It must be integrated by the treating physician into a dynamic care plan; it does not replace the therapeutic relationship.

Once the second opinion report is received, the following steps apply:

1. Review with your treating physician: Share the full report (not just a summary) with your primary consultant. Most physicians welcome a well-documented second opinion as it either provides validation or prompts a constructive review of the case. If the opinion conflicts, ask your doctor to explain their position in the context of the reviewing expert's findings.
2. Request a joint consultation if opinions differ: When two expert opinions significantly disagree, a multidisciplinary case conference — involving both the original team and the reviewing institution — is the most effective way to resolve uncertainty. This is now possible via video-conference.
3. Proceed with treatment or further investigation: If the second opinion confirms the diagnosis and treatment plan, proceed with confidence. If additional investigations are recommended (e.g., repeat biopsy, molecular profiling, additional imaging), these should be prioritised before irreversible treatment is initiated.
4. International medical travel planning: If the second opinion is from the institution you plan to travel to for treatment, the reviewing physician's report becomes the foundation of the pre-treatment planning. Ensure it includes a specific operative plan, estimated timeline, and preoperative preparation instructions.
5. Documentation: Keep all second opinion documents, imaging studies, and correspondence in a personal health record — digital or physical. These are invaluable if further changes in care occur or if additional opinions are sought in future.

Costs vary significantly by service type, institution, specialty, and geography:

• Online second opinion (major US academic centres): USD 500–2,500 per case for asynchronous written report. Mayo Clinic Online Second Opinion costs USD 700–1,000 for standard cases; Cleveland Clinic MyConsult is similar. Oncology tumour board reviews may cost more.
• Digital pathology second opinion only: USD 200–800 for subspecialty pathology review of slides from a major cancer centre.
• In-person consultation: USD 400–1,500+ for a specialist consultation at a US academic centre; UK private clinic second opinion consultation typically GBP 200–500.
• Indian specialist second opinion services: INR 5,000–25,000 (USD 60–300) for written telemedicine second opinion from senior oncologists at AIIMS, Tata Memorial Centre, or Manipal Hospitals.
• Insurance coverage (US): Many US insurance plans (BCBS, Aetna, UnitedHealth) cover specialist second opinions as preventive services, particularly for cancer diagnoses. Pre-authorisation may be required. Some plans specifically mandate a second opinion before certain major surgeries.
• Record retrieval fees: Hospitals in the US may charge a per-page fee for paper records (typically capped at USD 0.25/page); electronic records must be provided at minimal or no cost under HIPAA.
• Translation costs: Records in languages other than English require certified medical translation — typically USD 60–120 per page for complex medical reports.

Medical report review can be combined with and is complemented by the following:

• Genomic/molecular tumour profiling: Services such as Foundation Medicine (FoundationOne CDx), Guardant360 (liquid biopsy), and Tempus xT provide comprehensive molecular profiling of tumour tissue, identifying targetable mutations, microsatellite instability (MSI) status, and tumour mutational burden (TMB). Results can be incorporated into a second opinion review or interpreted independently by a molecular tumour board.
• Patient advocacy organisations: Disease-specific advocacy groups (e.g., LLS for leukaemia, NORD for rare diseases, CancerCare, Macmillan Cancer Support UK) can provide navigation assistance, peer support, and lists of specialist centres.
• Clinical trial registries: ClinicalTrials.gov (US), EU Clinical Trials Register, and ISRCTN list open trials by condition, stage, and location. A specialist second opinion is often the gateway to trial eligibility identification.
• Telemedicine platforms: General telemedicine services (Teladoc Health, Babylon Health, DocsApp) provide convenient access to a physician review but typically do not provide the subspecialty depth required for a second opinion on complex cancer or surgical decisions. They are, however, useful for minor conditions and for preparing a referral to a specialist service.
• Patient-held records and apps: Apps such as CommonHealth (US, FHIR-based), the NHS App (UK), and Apple Health allow patients to access and share their electronic health records directly with any provider, simplifying the second opinion process.
• MyMedicPlus Second Opinion Service: MyMedicPlus connects patients with specialist consultants at accredited international hospitals for remote case review, coordinating record transfer, translation, and specialist matching — see our second opinion service for details.